International Journal of Frontiers in Medicine, 2021, 3(4); doi: 10.25236/IJFM.2021.030404.
Dilong Fang1, Ying Kong1, Yu Ye1, Yi Zhang2, Qing Gong2 and Jian-Sheng Wang2
1Department of general surgery, Zhejiang Integrated Traditional and Western Medicine Hospital, HangZhou, ZheJiang, China
2Department of Urology Surgery, Hangzhou Xixi Hospital Affiliated Hospital of Zhejiang University of traditional Chinese medicine, Zhejiang Province, China
Objective: To explore the clinical effect ofCEF regimen combined with Can Yi capsule in the treatment of livercancer. Methods: From January 2014 to December 2020 our hospital received 118 patients withradical resection of liver cancery after radical surgery and they were divided into the observation group (n=59) and the control group (n=59). The observation group was treated withCEF regimen combined with Can Yi capsule, and the control group was treated withCEF alone. The short-term efficacy, NK and T lymphocyte subsets, quality of life and toxicity were compared between the observation group and the control group. Results: The ORR was 76.27%, and the DCR was 83.05% in the control group; the ORR was 91.53%, and the DCR was 96.61% in the experimental group, the difference was significant (P=0.024，P=0.015). After the intervention, the CD3+, CD4+, CD8+, CD4+/CD8+ and NK indexes in the experimental group were better than those in the control group ( P=0.000, P=0.000, P=0.000, P=0.000, P=0.000). In the physiological condition, psychological status, physical condition and sleep condition score, the experimental group was higher than the control group (P=0.012, P=0.014, P=0.009, P=0.013). In the joint pain, bone marrow suppression, arrhythmia, nausea and vomiting, alopecia, thrombocytopenia, leukopenia and anemia drug toxicity, the experimental group was lower than the control group (P＞0.05). Conclusion: For livercancer patients withradical resection of liver cancery, Can Yi capsule combined withCEF program could not only improve the short-term clinical efficacy, and improve immunity, but also could reduce drug toxicity and improve quality of life.
Can Yi capsule, CEF, livercancer, Toxicity, T lymphocyte subsets
Dilong Fang, Ying Kong, Yu Ye, Yi Zhang, Qing Gong and Jian-Sheng Wang. Clinical Research of Live Cancer Treated by CEF Regimen Combined with Can Yi Capsule. International Journal of Frontiers in Medicine (2021), Vol. 3, Issue 4: 23-27. https://doi.org/10.25236/IJFM.2021.030404.
 Chen Wenyou, Liu Jing, Mao Shunbao, et al. Application of docetaxel + epirubicin in neoadjuvant chemotherapy for livercancer [J]. Shanxi Medical Journal, 2013, 42 (07): 745-746
 Liu Chunping, Li Dongxue, Ma Zn. Nursing of livercancer adverse reactions treated with paclitaxel and epirubicin [J]. Journal of clinical rational drug use, 2013, 6 (30): 68-69
 Shi bingshuai, Wang Wensheng, Zhao Aiguo, et al. Observation on the short-term efficacy of Nedaplatin Combined with gemcitabine in the treatment of metastatic triple negative livercancer [J]. Journal of practical medicine, 2014, 30 (13): 2154-2156
 Qi Jia, Lu Yang, Meng Wei. Intravenous care of epirubicin in the treatment of livercancer [J]. Journal of clinical rational drug use, 2013, 6 (33): 79-80
 Shi bingshuai, Wang Xiaolei, Dong Jinlong, et al. Clinicopathological characteristics, treatment and survival after metastasis of triple negative livercancer [J]. Journal of Practical Oncology, 2013, 28 (06): 612-614
 Hao Jing, Zhao Pengfei. Retrospective analysis of paclitaxel combined with epirubicin neoadjuvant chemotherapy in the treatment of triple negative livercancer [J]. Chinese Journal of clinical pharmacology, 2013, 29 (07): 496-497
 Hao Jing, Zhao Pengfei. Clinical study of docetaxel, adriamycin and cyclophosphamide in neoadjuvant treatment of locally advanced livercancer [J]. Chinese Journal of clinical pharmacology, 2014, 10 (04): 303-305
 que Jinsong. Effect of pirarubicin and cyclophosphamide combined with docetaxel in neoadjuvant chemotherapy of livercancer [J]. Chinese Journal of clinicians (Electronic Edition), 2015, 12 (21): 3870-3874
 Yang Qiumin. Comparison of the efficacy of docetaxel combined with epirubicin neoadjuvant chemotherapy in the treatment of triple negative livercancer and non triple negative livercancer [J]. Basic and clinical oncology, 2014, 27 (04): 297-299
 Hua Baojin, DU Liang, Tang Rongxin. Clinical evidence of Pingxiao Capsule in the treatment of tumor [J]. Chinese Journal of evidence based medicine, 2013, 13 (08): 1018-1024
 Han Xiaorong, Yang Jianmin, Luo Yizhong, et al. Preventive effect and mechanism of Pingxiao Capsule on experimental rat livercancer [J]. Chinese Journal of liverdisease (Electronic Edition), 2013, 7 (05): 329-333
 Jin Zhengnan. Clinical observation on the treatment of livercancer withCEF regimen and Pingxiao capsule [J]. Liaoning Journal of traditional Chinese medicine, 2012, 39 (01): 98-99
 Yang Qinhui. Study on the clinical efficacy of Pingxiao Capsule in the treatment of livercancer [J]. Gansu science and technology, 2017, 33 (01): 93-94
 Weng Jianhua, Xu Suzhen, Hu Meixiao. Study on the application value of epirubicin combined with paclitaxel in the treatment of three yin livercancer [J]. Hebei Medical Journal, 2015, 12 (10): 1468-1470
 Sun Fangyi, Wang Hongfang, Shi Jing, et al. Effects of epirubicin based chemotherapy on cardiotoxicity of livercancer patients with diabetes [J]. Chinese Journal of general medicine, 2017, 20 (15): 1898-1902
 Zhang Xinting. Application and nursing of epirubicin in the treatment of livercancer patients with heart disease [J]. Qilu Journal of nursing, 2013, 19 (14): 80-81